RxDoctor Payments Data

Jennifer Bednarz, APRN

Nurse Practitioner · Des Plaines, ILNPI 1306498571

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,874 of the $11,016 with a category attached, or 89.6%. It is spread thinly across 60 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,016in general payments, 2019–2025

Across 471 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • AstraZeneca$710
  • Merck$696
  • Lilly USA, LLC$571
  • Takeda Pharmaceuticals U.S.A., Inc.$470
  • Johnson & Johnson$448
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$9,87490%
  • Education$1,14210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis57$1,116
AstraZeneca(2 entities)36$710
Merck34$696
Lilly USA, LLC13$571
Takeda Pharmaceuticals U.S.A., Inc.16$470
Johnson & Johnson18$448
Pharmacyclics LLC, An Abbvie Company16$437
Eisai Inc.19$412
Regeneron Healthcare Solutions, Inc.22$405
Astellas Pharma US Inc13$391
AbbVie18$341
Seagen Inc.12$307
Pfizer13$268
Incyte Corporation7$220
Amgen12$211
E.r. Squibb & Sons, L.L.C.11$207
Genentech USA, Inc.10$205
Bristol Myers Squibb7$198
ADC Therapeutics America, Inc.5$191
EMD Serono, Inc.10$180
Sanofi9$178
Daiichi Sankyo Inc.8$173
Blueprint Medicines Corporation5$137
Pharmacosmos Therapeutics Inc.6$131
Sobi, Inc2$122
Jazz Pharmaceuticals Inc.4$118
Ipsen Biopharmaceuticals, Inc5$115
Bayer6$111
GSK4$109
Scpharmaceuticals Inc.1$108
Tersera Therapeutics LLC3$97
Beigene USA, Inc.5$96
Servier Pharmaceuticals LLC4$88
Beone Medicines USA, Inc.1$85
Genmab U.S., Inc.3$80
Sanofi-aventis U.S. LLC1$78
Boehringer Ingelheim3$77
Recordati_rare_diseases_inc.3$71
Deciphera Pharmaceuticals Inc.3$63
Amneal Pharmaceuticals LLC2$57
Legend Biotech USA Inc.2$46
G1 Therapeutics, Inc.2$44
Blue Earth Diagnostics2$43
CTI Biopharma Corp.2$42
Agios Pharmaceuticals, Inc.2$41
Coherus Oncology, Inc.2$40
AVEO Pharmaceuticals, Inc.2$40
Array Biopharma Inc2$37
Stemline Therapeutics Inc.2$36
Iovance Biotherapeutics, Inc.1$32
GE HealthCare1$31
Springworks Therapeutics, Inc.1$30
Sumitomo Pharma America, Inc.1$29
Pharmaessentia USA Corporation1$29
Tempus AI, Inc1$28
Immunocore Limited1$25
Novo Nordisk1$25
Spectrum Pharmaceuticals Inc.1$25
Adaptive Biotechnologies Corporation1$24
Organon1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,016 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$114,353
Medicare patients
230
Services billed
2,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate20$335,481
RevlimidLenalidomide13$259,408
ImbruvicaIbrutinib15$225,919
RubracaRucaparib Camsylate11$99,635
EliquisApixaban75$50,242
Imatinib Mesylate13$14,728
XareltoRivaroxaban13$11,306
Anagrelide Hcl18$2,546
Exemestane27$2,460
Fentanyl14$2,071
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen64$1,445
Dexamethasone51$971
Hydroxyurea38$966
Bicalutamide17$943
Ondansetron Hcl111$912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$220$335,48120 claims
Bristol Myers SquibbRevlimid$198$259,40813 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$437$225,91915 claims
PfizerEliquis$268$50,24275 claims
Johnson & JohnsonXarelto$448$11,30613 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$57$52034 claims
Lilly USA, LLCOlanzapine$571$43428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Des Plaines

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →